IP Library › Granted Patent US 12,466,854
Granted Patent B2
US 12,466,854 · App. 18/850,224 · Granted Nov 11, 2025

Peptide useful for the transport of molecules through cell barriers

Inventors: Charlotte Lombardi (Rochefort Samson, FR); Marcelle Moulin (Annecy, FR); Catherine Ghezzi (Grenoble, FR)
Assignees: UNIVERSITÉ GRENOBLE ALPES; INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
C07K7/083C07K7/08C07K16/18C07K2317/569C07K2319/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,854
App. No.
18/850,224
Granted
Nov 11, 2025
Kind
B2
Abstract

A new peptide and its use as a vector for the transport of molecules after conjugation through cellular barriers for the diagnosis, prognosis or treatment of pathologies of the central nervous system (CNS).

Claims (13)

1 . A peptide comprising a peptide of amino acid sequence SEQ ID NO 1.

2 . A peptide conjugate comprising the peptide according to claim 1 , wherein the peptide is covalently linked to a molecule of interest, directly or via a linker.

3 . The peptide conjugate according to claim 2 , wherein the linker is composed of 1 to 6 amino acids.

4 . The peptide conjugate according to claim 2 , wherein the molecule of interest is chosen from the group consisting of an antibody, a DNA, an RNA, a peptide, and a drug.

5 . The peptide conjugate according to claim 4 , wherein the antibody is a single domain antibody.

6 . The peptide conjugate according to claim 5 , wherein the single domain antibody is an anti-Tau single domain antibody that comprises the amino acid sequence SEQ ID NO: 3.

7 . The peptide conjugate according to claim 6 comprising the amino acid sequence SEQ ID NO: 4.

8 . A nucleic acid sequence encoding the peptide according to claim 1 , wherein the nucleic acid sequence further encodes a molecule of interest, and wherein the peptide is covalently linked to the molecule of interest directly or via a linker further encoded by the nucleic acid sequence.

9 . An expression vector comprising a nucleic acid sequence as defined in claim 8 .

10 . A method comprising

diagnosing, prognosing, or treating a pathology of the central nervous system (CNS) with the peptide conjugate according to claim 2 .

11 . The method according to claim 10 , wherein the CNS pathology is chosen from the group consisting of brain tumors, cerebrovascular accidents (CVA), Huntington's disease, multiple sclerosis and tauopathies.

12 . The method according to claim 11 , wherein the tauopathies are chosen from the group consisting of Parkinson's disease, Pick's disease, and Alzheimer's disease.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2024
From: LOMBARDI, CHARLOTTE; MOULIN, MARCELLE; GHEZZI, CATHERINE
To: UNIVERSITÉ GRENOBLE ALPES; INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
Reel/Frame 068677/0728 →
Priority Claims (1)
FR 22/03309 · Apr 11, 2022 · national
Continuity (1)
Related Publication 20250109169A1 · Apr 3, 2025
References Cited (17)
US 10590191B2 · Fagret · 2020 [cited by examiner]
FR 3058143A1 · 2018 [cited by applicant]
WO 2018078140A1 · 2018 [cited by applicant]
Mullard, A. Nat Rev Drug Discov. Dec. 2024;23(12):883. doi: 10.1038/d41573-024-00180-7. PMID: 39487218. [cited by examiner]
Aug. 8, 2023 International Search Report issued in International Patent Application No. PCT/FR2023/050519. [cited by applicant]
Zhou et al., “Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases”, WIREs Nanomedicine and Nanobiotechnology, 2021, e1695. [cited by applicant]
Schwarze et al., “In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse”, Science, vol. 285, Sep. 3, 1999, pp. 1569-1572. [cited by applicant]
Patel et al., “Crossing the Blood-Brain Barrier: Recent Advances in Drug Delivery to the Brain”, CNS Drugs, Jan. 18, 2017. [cited by applicant]
Pardridge, William M, “Blood-Brain Barrier Drug Targeting: the Future of Brain Drug Development”, Molecular Interventions, vol. 3, Issue 2, Mar. 2003, pp. 90-105. [cited by applicant]
Pardridge, William M, “CSF, blood-brain barrier, and brain drug delivery”, Expert Opinion on Drug Delivery, 2016. [cited by applicant]
Oller-Salvia et al., “Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery”, Chem. Soc. Rev., 2016, vol. 45, No. 17, pp. 4690-4707. [cited by applicant]
Dong, Xiaowei, “Current Strategies for Brain Drug Delivery”, Theranostics 2018, vol. 8, Issue 6, pp. 1481-1493. [cited by applicant]
Boer et al., “Strategies to Improve Drug Delivery Across the Blood-Brain Barrier”, Clin Pharmacokinet, 2007, vol. 46, No. 7, pp. 553-576. [cited by applicant]
Kardani et al., “Cell penetrating peptides: the potent multi-cargo intracellular carriers”, Expert Opinion on Drug Delivery, 2019, vol. 16, No. 11, pp. 1227-1258. [cited by applicant]
Cho et al., “Blood-brain-barrier spheroids as an in vitro screening platform for brain-penetrating agents”, Nature Communications, 2017, pp. 1-14. [cited by applicant]
Bera et al., “Structural Elucidation of the Cell-Penetrating Penetratin Peptide in Model Membranes at the Atomic Level: Probing Hydrophobic Interactions in the Blood-Brain Barrier”, Biochemistry, 2016, vol. 55, pp. 4982… [cited by applicant]
Abbott et al., “Structure and function of the blood-brain barrier”, Neurobiology of Disease, vol. 37, 2010, pp. 13-25. [cited by applicant]